The asthma medication Advair and a related drug will bear stronger warnings of an increased risk of death associated with one of their ingredients. The revised warnings apply to Advair and Serevent, Food and Drug Administration spokeswoman Laura Alvey said Monday. Advair is GlaxoSmithKline’s best-selling product, and Serevent is another of the British company’s drugs.
